Global Carcinoembryonic Antigen (CEA) Market by Application (Gastrointestinal Cancer [Colon Cancer, Pancreatic Cancer, Rectal Cancer, Liver Cancer, Stomach Cancer, Oesophageal Cancer, Gallbladder Cancer, Anal Cancer], Breast Cancer, Lung Cancer, Ovarian C

The global carcinoembryonic antigen (CEA) market is anticipated to expand at a considerable CAGR during the forecast period, 2020 – 2026. Carcinoembryonic antigen (CEA) is a group of glycoprotein present in the body fluids of the fetus and embryo and in the gastrointestinal tract. It is normally found in embryonic endodermal epithelium and also present in the gastrointestinal cells, mucosal cells of the colorectum, and small amounts are present in the blood but the production stops before birth. CEA is not present in the healthy adults but cancer patients show concentrations of CEA. A carcinoembryonic antigen test measures the amount of carcinoembryonic antigen protein in the blood and helps to manage and diagnose certain types of cancers like colorectal or colon cancer, breast cancer, liver cancer, ovarian cancer, lung cancer.

Market Trends, Drivers, Restraints, and Opportunities:

• Increasing per capita healthcare expenditure and growing demand for minimally invasive diagnostic procedures are some of the key trends driving the growth of the CEA market and thus fueling the growth of the market.
• Technological innovations and advancements in CEA diagnostics are driving the growth of the market.
• Increasing incidence rate for cancer disease is a major factor contributing to the growth of the market size.
• Ineffective approach for cancer detection at initial stage, is a key restraint of the market growth.
• Lack of awareness regarding the application of carcinoembryonic antigen tests hampers the growth of the
• Risk of infections by CEA testing will restrain the market growth of the global carcinoembryonic antigen during the forecast period.
• Constant development of novel immunological techniques, is a key market opportunity.

Scope of the Report

The report on the global carcinoembryonic antigen (CEA) market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report. AttributesDetailsBase Year2019Historic Data2018–2019Forecast Period2020–2026Regional ScopeAsia Pacific, Europe, North America, Middle East & Africa, and Latin AmericaReport CoverageCompany Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Global Carcinoembryonic Antigen (CEA) Market Segment Insights:

Based on product types, the global carcinoembryonic antigen (CEA) market is segmented into gastrointestinal cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer, and thyroid cancer. The gastrointestinal cancer further categorized into colon, pancreatic, rectal, liver, stomach, oesophageal, gallbladder, and anal cancer. Gastrointestinal cancer accounted for the majority of the market share in 2019 and is one of the most common cancers globally. It occurs in developing countries affecting a major chunk of the global population. In terms of gender, the market is bifurcated into male and female. Carcinoembryonic antigen for males held the majority of the market share. According to the American Cancer Society, about half of men get cancer at some point of their lives, as compared to one-third of women population. In terms of end-users, the global carcinoembryonic antigen (CEA) market is fragmented into hospitals, diagnostic centers, cancer centers, research and academic institutes. The hospitals had a major share in the market. Increasing incidence of cancer all across the world is responsible for the largest share of hospitals in global market. Also, CEA tests in hospitals have certain benefits such as being connected to the health care system through the IoT, and improved diagnosis accuracy as all the necessary patient data are always available. The research and academic segment is projected to increase at a faster rate during forecast period. On the basis of regions, the global carcinoembryonic antigen (CEA) market is segmented into Asia Pacific, Europe, North America, the Middle East & Africa, and Latin America. North America dominated the global market in terms of the revenue share in 2019 and is anticipated to witness the same trend over the forecasting period due to high incidence rates of cancers, presence of sophisticated healthcare infrastructure, and high patient awareness levels. Asia pacific is expected to account for a key share of the market in the region by 2026 due to presence of untapped opportunities, constantly improving healthcare infrastructure, economic development.

Competitive Landscape:

Major companies in the global carcinoembryonic antigen (CEA) market include F. Hoffmann-La Roche Ltd., Quest Diagnostics, GenWay Biotech Inc., Correlogic Systems, Inc., Creative Diagnostics, Omega Diagnostics Group PLC, RayBiotech Inc., and Boster Biological Technology. Global CEA market share is very competitive in nature and is dominated by very few players hence the market players are engaged in developing product variants to amplify their market share and gain traction in global marketplace. The companies are engaging in strategic acquisitions such as product launches, R&D, agreements, mergers & acquisition, and collaborations to gain market share. Manufacturer face constant pressure to introduce new and technologically advanced products with more sensitivity in the market. For instance, The American Society of Clinical Oncology endorsed the usage of carcinoembryonic antigen testing for staging/diagnosis, detection of recurrence, monitoring treatment and screening for hepatic metastases in patients with colon cancer.

The Global Carcinoembryonic Antigen (CEA) Market has been segmented on the basis of

Application

• Gastrointestinal Cancer
• Breast Cancer
• Lung Cancer
• Ovarian Cancer
• Prostate Cancer
• Thyroid Cancer

End Users

• Hospitals
• Diagnostic Centers
• Cancer Centers
• Research and Academic Institutes

Gender

• Male
• Female

Regions

• Asia Pacific
• Europe
• North America
• Middle East & Africa
• Latin America